



**Board of Directors Report  
For the Financial Period April/June 2023  
(Consolidated Statements)**

We present the Board of Directors' report on the consolidated financial statements for the period from April 1, 2023, to June 30, 2023, for the Egyptian International Pharmaceutical Industries Company (EIPICO).

**Company Overview:**

**Purpose:** EIPICO engages in pharmaceuticals, medical products, cosmetics, chemicals, veterinary products, pesticides, dietary supplements, medical plants, special foods, glass ampoule manufacturing, and plastic pharmaceutical packaging. It operates within and beyond Egypt.

**The duration of the company** has been extended to twenty-five years, commencing from December 18, 2005, and ending on December 17, 2030, with the possibility of renewal for a similar period by a decision of the Extraordinary General Assembly.

**The company is subject to Law No. 43 of 1974, as amended by Law No. 32 of 1977.**

**Key Data:**

Authorized Capital: EGP 1,500,000,000

Paid-Up Capital: EGP 991,705,000

Issued Capital: EGP 991,705,000

Nominal Value per Share: EGP 10

Commercial Registry Number and Date: 11116, December 3, 1980

As we conclude the second quarter of April/June 2023, we present the following significant achievements:

**1. Net Sales (Revenue):**

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Domestic Market Net Sales	1,286	1,100	186	16.9%
Tender Sales Net Sales	203	186	16.8	9%
Export Net Sales	779	446	333	74.8%
Toll Sales to Others	2.2	1.2	0.3	15.6%
Total Company Net Sales	2,270	1,734	536	30.9%



2.

**Cost of Goods Sold:**

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Cost of Goods Sold	1.177	967	210	21.8%
Cost of Goods Sold to Net Sales	51.8%	55.8%	(4 %)	

3. **Production:**

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Production Value	2,534	2,027	507	25%

4. **Profitability:**

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Gross Profit	1,093	767	326	43
Net Profit Before Tax	659	393	266	68
Net Profit After Tax	509	304	205	67

5. **Assets under construction:**

Category	During the Period (Million EGP)	December 31, 2022 (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Assets under construction	2,391	866	1,525	176%

✱



## 6. Cash Flows and Cash Balances:

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Cash Flows from Operations	(76)	(33)	(43)	129%
Cash Flows from Investing	(1524)	(115)	(1409)	1224%
Cash Flows from Financing	1460	273	1187	435.4%
Net Cash Flow for the Period	(139)	125	(264)	(211.9%)
Exchange Rate Impact on Cash	231	82	150	183.5%
Cash Balance at the Beginning	483	312	171	54.9%
Cash Balance on June 30, 2023	575	518	57	11%

## 7. Capital:

Category	During the Period (Million EGP)	Comparable Period (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Capital	991.71	991.71	0	0

## 8. Treasury Shares:

Category	During the Period (Million EGP)	December 31, 2022 (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Treasury Shares	0	0	0	0



9. Equity (Including Surplus of the Period):

Category	During the Period (Million EGP)	December 31, 2022 (Million EGP)	Increase/Decrease (Million EGP)	Percentage (%)
Equity (Including Surplus)	3,453	3,242	211	7%

Accept our sincere regards and respect.

Chairman and Managing Director

Dr. Ahmed Kelani

